## CITATION REPORT List of articles citing



DOI: 10.1002/cpt.501 Clinical Pharmacology and Therapeutics, 2016, 100, 672-684.

Source: https://exaly.com/paper-pdf/64595489/citation-report.pdf

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
8	Value Assessment in the Regulatory Context. <i>Value in Health</i> , <b>2017</b> , 20, 296-298	3.3	2
7	A Benefit-Risk Analysis Approach to Capture Regulatory Decision-Making: Multiple Myeloma. <i>Clinical Pharmacology and Therapeutics</i> , <b>2018</b> , 103, 67-76	6.1	8
6	Accelerating anticancer drug development - opportunities and trade-offs. <i>Nature Reviews Clinical Oncology</i> , <b>2018</b> , 15, 777-786	19.4	32
5	Using a Benefit-Risk Analysis Approach to Capture Regulatory Decision Making: Melanoma. <i>Clinical Pharmacology and Therapeutics</i> , <b>2019</b> , 106, 123-135	6.1	4
4	Exposure-Response-Based Product Profile-Driven Clinical Utility Index for Ipatasertib Dose Selection in Prostate Cancer. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , <b>2019</b> , 8, 240-248	4.5	6
3	Using a Benefit-Risk Analysis Approach to Capture Regulatory Decision Making: Renal Cell Carcinoma. <i>Clinical Pharmacology and Therapeutics</i> , <b>2020</b> , 107, 495-506	6.1	4
2	Patient-Centered Approach to Benefit-Risk Characterization Using Number Needed to Benefit and Number Needed to Harm: Advanced Non-Small-Cell Lung Cancer. <i>JCO Clinical Cancer Informatics</i> , <b>2020</b> , 4, 769-783	5.2	1
1	Predicting Regulatory Product Approvals Using a Proposed Quantitative Version of FDAfs Benefit-Risk Framework to Calculate Net-Benefit Score and Benefit-Risk Ratio. <i>Therapeutic Innovation and Regulatory Science</i> , <b>2021</b> , 55, 129-137	1.2	2